Adaptive Biotechnologies 주식 (NASDAQ: ADPT)

에 대한 최신 뉴스 Adaptive Biotechnologies (NASDAQ:ADPT) 주식

Adaptive Biotechnologies

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adeptus Health

Equities

News

Markets

ETFs

ADPT

ARKQ

BLDE

PLTR

RXRX

TDOC

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 팔란티어 테크놀로지스(NYSE:PLTR)에 주목할 만한 투자를 했다. 이는 인공 지능(AI) 부문이 탄력을 받으면서 이루어진 움직임이다.

캐시 우드의 아크 인베스트는 AI 열풍 속에서 516만 달러 가치의 팔란티어 주식 매수

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Buy and raises the price target from $7 to $8.

Price Target

Analyst Ratings

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $8

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.
Shares of Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) rose sharply in today's session after the company reported better-than-expected fourth-quarter financial results and approved a $1 billion share buyback.
Jabil reported fourth-quarter revenue of $6.96 billion, down by 17.7% year-on-year, beating the analyst consensus estimate of $6.59 billion. The print manufacturing company's adjusted EPS of $2.30 beat the analyst consensus estimate of $2.22.
Jabil shares jumped 11.2% to $126.18 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>SBC Medical Group Holdings Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NYSE">SBC</a>) jumped 25.4% to $10.01.</li>
<li>Gaotu Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) shares jumped 25.4% to $3.65.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) gained 24.1% to $4.9650.</li>
<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) gained 21.7% to $10.13.</li>
<li>Ispire Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) surged 18.6% to $6.91 following FY24 financial results.</li>
<li>Studio City International Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 17.8% to $7.43.</li>
<li>KE Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) surged 17.4% to $19.22. Shares of Chinese stocks traded higher following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>H World Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) gained 16.7% to $36.60. Shares of Chinese stocks traded higher following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) gained 14.4% to $71.19.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 14.2% to $109.37 following strong quarterly results.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) jumped 14.2% to $43.60.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) gained 10% to $100.78.</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) climbed 9.9% to $31.19 after the company announced it plans a $2.5 billion share repurchase program and issued its third-quarter RASM guidance. Also, the company announced it reduced headcount through controlled hiring and attrition and has contracts with all labor groups.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) gained 9.7% to $104.73 following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) rose 9.1% to $55.74.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) gained 6.6% to $138.71.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41045737/top-3-materials-stocks-youll-regret-missing-this-quarter">Top 3 Materials Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

BABA

BEKE

New Oriental Education & Technology Group

GSX Techedu Inc. American Depositary Shares

GOTU

HTHT

ISPR

TCOM

YUMC

Jabil Posts Upbeat Earnings, Joins Micron Technology, Southwest Airlines And Other Big Stocks Moving Higher On Thursday

<h3>Gainers</h3>
<ul>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock moved upwards by 66.4% to $6.4 during Thursday's regular session. The market value of their outstanding shares is at $6.6 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares increased by 49.13% to $3.46. The market value of their outstanding shares is at $6.1 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares rose 28.62% to $5.14. The company's market cap stands at $758.7 million. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) stock increased by 25.64% to $4.36. The company's market cap stands at $272.0 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock increased by 20.3% to $1.25. The market value of their outstanding shares is at $6.7 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock rose 18.51% to $7.04. The market value of their outstanding shares is at $368.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) stock decreased by 19.4% to $1.75 during Thursday's regular session. The market value of their outstanding shares is at $91.3 million. As per the news, the H1 earnings report came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares declined by 18.99% to $1.92. The company's market cap stands at $2.5 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares decreased by 14.47% to $5.64. The market value of their outstanding shares is at $8.2 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares declined by 13.31% to $8.34. The company's market cap stands at $13.0 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 11.02% to $0.6. The company's market cap stands at $4.5 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 10.17% to $1.67. The market value of their outstanding shares is at $21.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ERNA

FBRX

FULC

KAPA

KTTA

LUCY

TBIO

TOVX

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 200 points on Thursday.
The Dow traded up 0.47% to 42,110.56 while the NASDAQ rose 0.19% to 18,117.40. The S&amp;P 500 also rose, gaining, 0.21% to 5,734.09.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41045161/how-to-earn-500-a-month-from-costco-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Costco Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Materials shares jumped by 1.8% on Thursday.
In trading on Thursday, energy shares fell by 1.9%.
Top Headline
U.S. initial jobless claims fell by 4,000 from the prior week to 218,000 during the period ending September 21, compared to estimates of 225,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares shot up 71% to $3.96 after the company announced a partnership with Beckman Coulter Life Sciences to revolutionize DNA and mRNA synthesis.</li>
<li>Shares of Pasithea Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) got a boost, surging 66% to $6.37 after the company announced safety, tolerability, pharmacokinetic and preliminary efficacy data from the first 2 cohorts of patients in its Phase 1 clinical trial of PAS-004.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares were also up, gaining 25% to $5.00.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) shares dropped 16% to $53.65 following mixed third-quarter financial results.</li>
<li>Shares of Ryde Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NYSE">RYDE</a>) were down 30% to $0.81 after the company announced a $4.5 million public offering at $0.85 per unit.</li>
<li>MDxHealth SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) was down, falling 21% to $2.00 after the company announced the pricing of a $40 million offering of 20 million shares at $2.00 per share</li>
</ul>
Commodities In commodity news, oil traded down 2.4% to $68.00 while gold traded up 0.2% at $2,688.80.
Silver traded up 1.3% to $32.435 on Thursday, while copper rose 2.9% to $4.6195.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.13%, Germany's DAX climbed 1.52% and France's CAC 40 jumped 2.08%. Spain's IBEX 35 Index rose 1.39%, while London's FTSE 100 rose 0.12%.
Bank lending to households in the Eurozone increased by 0.6% year-over-year to €6.891 trillion in August compared to a 0.5% rise in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -21.2 heading into October versus a revised reading of -21.9 in the prior period.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 jumping 2.79%, Hong Kong's Hang Seng Index jumping 4.16%, China's Shanghai Composite Index gaining 3.61% and India's BSE Sensex gaining 0.78%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month.
Economics
<ul>
<li>U.S. core PCE prices increased by 2.8% from the prior quarter during the second quarter compared to a 3.7% gain in the previous period.</li>
<li>U.S. durable goods orders came in mostly unchanged from the previous month in August versus the revised 9.8% jump in the earlier period.</li>
<li>U.S. initial jobless claims fell by 4,000 from the prior week to 218,000 during the period ending September 21, compared to estimates of 225,000.</li>
<li>The US economy expanded at an annualized rate of 3% during the second quarter versus a revised 1.6% increase in the first quarter.</li>
<li>Pending home sales in the U.S. rose by 0.6% from the prior month in August versus market estimates of a 0.3% increase.</li>
<li>U.S. natural-gas stocks rose 47 billion cubic feet in the week ended Sept. 20, compared to market estimates of a 52 bcf gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41045737/top-3-materials-stocks-youll-regret-missing-this-quarter">Top 3 Materials Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Eurozone

Intraday Update

CNXC

MDXH

RYDE

Crude Oil Down Over 2%; US Initial Jobless Claims Fall

General

Adaptive Receives IVDR Certification For clonoSEQ In European Union

JP Morgan analyst Rachel Vatnsdal maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $5 to $6.

JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $6

Guidance

Adaptive Biotechnologies Expects 2024 Revenue For The MRD Business To Be $140M-$145M, Up From Prior Range Of $135M-$140M

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.33) by 6.06 percent. The company reported quarterly sales of $43.190 million which beat the analyst consensus estimate of $38.664 million by 11.71 percent. This is a 11.72 percent decrease over sales of $48.926 million the same period last year.

Earnings

Earnings Beats

Adaptive Biotechnologies Q2 2024 GAAP EPS $(0.31) Beats $(0.33) Estimate, Sales $43.190M Beat $38.664M Estimate

On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), a move that comes as the AI sector gains momentum.
The PLTR Trade
Ark Invest, through its ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), purchased 199,372 shares of Palantir, a significant addition to its portfolio. The value of this trade, based on the closing price of $25.88 on the same day, stands at approximately $5.16 million.
Palantir has recently been praised as an &#8216;AI Halo&#8217; play by momentum investors. The company was added to BofA Securities&#8217; top 10 best U.S. ideas list for the third quarter, highlighting its <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39582335/momentum-investor-praises-palantir-as-ai-halo-play-highlights-datadog-as-software-bottom">growing popularity</a> in the AI sector. Joe Terranova of Virtus Investment Partners explained that Palantir is a key player in the AI space, participating actively in the AI halo.
Palantir co-founder Peter Thiel recently <a href="https://www.benzinga.com/news/24/07/39569675/palantirs-peter-thiel-says-its-very-strange-that-most-money-in-ai-is-being-made-by-only-one-company">shared his insights</a> on the AI landscape at the Aspen Ideas Festival, drawing parallels between the dot-com bubble and the current state of AI.
Other Key Trades:
<ul>
<li>Ark Invest&#8217;s ARKG bought shares of Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>). </li>
<li>ARKK purchased shares of Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>). ARKQ also added shares of Blade Air Mobility Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) to its portfolio. </li>
<li>ARKF sold shares of Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>).</li>
</ul>
Read Next: <a href="https://www.benzinga.com/markets/equities/24/06/39562285/jim-cramer-says-trumps-return-to-white-house-could-be-good-for-your-portfolio-hate-him-or-like-h?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Says Trump&#8217;s Return To White House Could Be &#8216;Good For Your Portfolio:&#8217; &#8216;Hate Him Or Like Him&#8217;</a>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor

The meeting will be taking place from May 31-June 4 in Chicago. Company will also present&nbsp;at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually.

Adaptive Biotechnologies Says Its Next-generation Sequencing-based clonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 17.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $41.873 million which beat the analyst consensus estimate of $38.784 million by 7.96 percent. This is a 11.23 percent increase over sales of $37.647 million the same period last year.

Adaptive Biotechnologies Q1 2024 GAAP EPS $(0.33) Beats $(0.35) Estimate, Sales $41.873M Beat $38.784M Estimate

U.S. stock futures were lower this morning, with the Nasdaq futures declining over 100 points on Friday.
Shares of Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/24/04/38324337/netflix-q1-earnings-highlights-revenue-beat-eps-beat-9-33-million-paid-subs-added-ad-tier-plan-upda">first-quarter results.</a>
Netflix reported upbeat earnings and sales results for its first quarter. The company added 9.33 million paid net new subscribers in the first quarter to bring the company to a total of 269.60 million.
Netflix shares fell 6% to $573.81 pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) shares fell 12.3% to $7.37 in pre-market trading after surging 12% on Thursday.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares declined 11.4% to $2.07 in pre-market trading. Adaptive Biotechnologies is expected to report financial results for the first quarter 2024 after the closing bell on May 7, 2024.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) fell 6.1% to $27.40 in pre-market trading.</li>
<li>SAGE Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined 5.6% to $12.30 in pre-market trading. The company recently announced topline results from Phase 2 PRECEDENT study of dalzanemdor for the treatment of people with mild cognitive impairment in Parkinson&#8217;s Disease.</li>
<li>DocGo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) shares fell 5.5% to $3.23 in pre-market trading.</li>
<li>Sunnova Energy International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 4.5% to $3.61 in pre-market trading.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) fell 3.8% to $3.85 in pre-market trading.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) shares fell 2.9% to $61.13 in pre-market trading after Exane BNP Paribas downgraded the stock from Neutral to Underperform.</li>
</ul>

Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38329059/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-friday">Netflix, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Friday</a>

CRML

DCGO

NFLX

NOVA

SAGE

Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Shares of Wang &amp; Lee Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) rose sharply in today's pre-market trading after the company reported a year-over-year <a href="https://www.benzinga.com/quote/WLGS/earnings">increase in FY23 financial results</a>.
Wang &amp; Lee Group posted a FY23 loss of 2 cents per share, versus a year-ago loss of 5 cents per share. The company's revenue came in at $6.83 million versus, $4.17 million in the year-ago period, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Wang &amp; Lee Group shares jumped 37.7% to $0.7220 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading" id="h-gainers">Gainers</h3>
<ul>
<li>Redwoods Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWOD#NASDAQ">RWOD</a>) shares gained 141% to $17.83 in pre-market trading after falling around 3% on Thursday.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) gained 75.6% to $2.53 in pre-market trading after gaining over 7% on Thursday.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) gained 30% to $0.4261 in pre-market trading. The company on Wednesday announced it entered into a securities purchase agreement with an institutional investor in the amount of $360,000.</li>
<li>HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) shares rose 24.7% to $1.61 in pre-market trading after falling 4% on Thursday.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) gained 22% to $0.2927 in pre-market trading. SuperCom shares fell around 33% on Thursday after the company priced a $2.9 million registered direct offering.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) rose 19.3% to $5.01 in today's pre-market trading after jumping 30% on Thursday. Bio-Path announced a $1.2 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Centogene N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTG#NASDAQ">CNTG</a>) shares gained 19.3% to $0.5513 in pre-market trading.</li>
<li>Kineta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) rose 14.7% to $0.5601 in pre-market trading. Kineta was recently granted a US patent titled &#8216;Proteasome activity enhancing compounds (including methods for treating cancer or tumors).&#8217;</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) shares gained 10.5% to $12.12 in pre-market trading. Apollo Global Management and Sony Group Corp. are reportedly in talks on a joint offer for Paramount Global.</li>
</ul>
<h3 class="wp-block-heading" id="h-losers">Losers</h3>
<ul>
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) fell 22.4% to $0.66 in pre-market trading after jumping around 29% on Thursday. BioNexus Gene Lab agreed to invest RM 1.2 million in Ascension Innovation (AISB) to advance digital health innovation through AI adoption in healthcare.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) fell 19.9% to $0.6407 in pre-market trading after surging 65% on Thursday.</li>
<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) fell 19.3% to $0.3396 in pre-market trading after gaining around 98% on Thursday.</li>
<li>AGBA Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGBA#NASDAQ">AGBA</a>) fell 13.6% to $0.89 in pre-market trading. AGBA Group Holding shares jumped 155% on Thursday higher after the company announced it entered into a definitive merger agreement with Triller.</li>
<li>Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) declined 12.3% to $0.5426 in pre-market trading after falling over 20% on Thursday. Spectaire Holdings recently signed a distribution partnership agreement with a Fortune 1000 Energy Company.</li>
<li>Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) shares fell 12.1% to $5.07 in pre-market trading.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares declined 11.4% to $2.07 in pre-market trading. Adaptive Biotechnologies is expected to report financial results for the first quarter 2024 after the closing bell on May 7, 2024.</li>
<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 11.1% to $0.3870 in pre-market trading. Soligenix shares fell around 15% on Thursday after the company announced the pricing of a $4.75 million public offering.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) fell 10.2% to $2.65 pre-market trading after jumping around 32% on Thursday.</li>
<li>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) fell 6% to $573.81 pre-market trading. Netflix reported upbeat earnings and sales results for its first quarter. The company added 9.33 million paid net new subscribers in the first quarter to bring the company to a total of 269.60 million.</li>
</ul>

Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38329059/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-friday">Netflix, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Friday</a>

AGBA

BGLC

BPTH

CNTG

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HUBC

ISPC

LTRN

PARA

RWOD

SNGX

SPCB

SPEC

TIRX

TPET

WLGS

ZCMD

Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Buy and lowers the price target from $6 to $5.

BTIG Maintains Buy on Adaptive Biotechnologies, Lowers Price Target to $5

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) announced Tuesday, April 3, that after a strategic review, the company will operate two businesses — Minimal Residual Disease (MRD) and Immune Medicine (IM) — internally.
The company will also restructure each business with dedicated resources and separate segment reporting. 
Under this structure, Adaptive preserves its strong capital position, which will bridge the MRD business to profitability and support targeted&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38056878/adaptive-biotechnologies-provides-strategic-review-update-and-announces-preliminary-first-quarter-" rel="noreferrer noopener">investments in Immune Medicine</a>.
Adaptive Biotechnologies reported the first-quarter fiscal year 2024 preliminary sales of $41 million-$43 million versus the consensus of $38.21 million.
MRD revenue of approximately $31 million &#8211; $32 million for the first quarter of 2024, up 47% year-over-year.
Adaptive Biotechnologies announced that Tycho Peterson will depart the company as CFO. 
Kyle Piskel, the company&#8217;s Principal Accounting Officer, will succeed Peterson as full-time CFO. Piskel served as the company&#8217;s interim CFO from February to June 2022.
William Blair writes that despite investor expectations for separating its two businesses, external factors like the macro environment limit Adaptive&#8217;s control over its options.&nbsp;
Feedback from potential buyers/partners suggests that the MRD business would fetch a higher valuation once it reaches cash flow breakeven in the first half of 2026, while the IM business would gain more value as it validates assets within its programs.&nbsp;
While under different circumstances, the current execution of both businesses might have led to a higher valuation, Adaptive acknowledges that external factors are beyond its control.&nbsp;
William Blair analyst says that maintaining both businesses together, with a focused approach on high ROI projects, offers long-term valuation upside.&nbsp;
The analyst reiterates the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/ADPT/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock</a>.
Price Action: ADPT shares are down 7.05% at $2.77 on the last check Wednesday.

Analyst Color

Health Care

Reiteration

Adaptive Biotechnologies Names New CFO Preserves Strong Capital Position

WIIM

Adaptive Biotechnologies shares are trading lower. The company yesterday provided a strategic review and announced preliminary Q1 2024 revenue.

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update, including the conclusion of its recent strategic review, preliminary revenue for the first quarter ended March 31, 2024, and transition of the chief financial officer role. &nbsp;
Strategic Review Update
After evaluating a number of potential opportunities as part of the strategic review, Adaptive's management team and board of directors concluded that the current best outcome to maximize shareholder value is to operate the MRD and Immune Medicine businesses internally within Adaptive while increasing their independence from one another by restructuring each business with dedicated resources and separate segment reporting. Importantly, under this structure, Adaptive preserves its strong capital position which will bridge the MRD business to profitability and support targeted investments in Immune Medicine.
Management will provide further details on the process and outcome of the strategic review during the conference call this afternoon.
First Quarter 2023 Preliminary, Unaudited Revenue Results
<ul>
<li>Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.</li>
<li>MRD revenue of approximately $31 to $32 million for the first quarter of 2024, an increase of approximately 47% compared to the first quarter of 2023.</li>
</ul>
CFO Transition
Adaptive Biotechnologies announced that Tycho Peterson, chief financial officer (CFO), will be departing the company to pursue another opportunity. Kyle Piskel, who currently serves as the company's Principal Accounting Officer and has held various financial roles at Adaptive over the past 8 years, will succeed Tycho as full-time CFO. Kyle previously served as the company's Interim CFO from February to June 2022 and brings over 15 years of financial expertise to the role.
"I am excited to announce Kyle as our new chief financial officer," said Chad Robins, chief executive officer and co-founder, Adaptive Biotechnologies. "I am confident he has the business knowledge to operate and execute, with the necessary guardrails in place, so that our team can maximize the full value of both MRD and Immune Medicine businesses. I would like to thank Tycho for his financial leadership and significant contributions to Adaptive over the past two years, including his leadership during the strategic review process. We wish him success in his next endeavor."
"I'm proud of the great work we accomplished together through a critical time in the company's evolution over the past two years," said Tycho Peterson, chief financial officer, Adaptive Biotechnologies. "Adaptive has a bold vision and world class science and is just beginning to unlock the potential on both its MRD and Immune Medicine businesses. I am confident in the future prospects of the business, and I look forward to following Adaptive's continued progress and success."

Adaptive Biotechnologies Provides Strategic Review Update And Announces Preliminary Q1 2024 Revenue Of $41M-$43M Vs $38.21M Est.

Management

Adaptive Biotechnologies Tycho Peterson, Chief Financial Officer Will Be Departing The Company To Pursue Another Opportunity. Kyle Piske Will Succeed Tycho As Full-time CFO

<h3>Gainers</h3>
<ul>
<li>Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) stock rose 24.6% to $3.34 during Thursday's pre-market session. The company's market cap stands at $257.9 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock moved upwards by 24.32% to $1.38. The market value of their outstanding shares is at $33.4 million. </li>
<li>KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) shares moved upwards by 15.83% to $16.68. The company's market cap stands at $576.4 million. </li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock increased by 14.83% to $12.54. The company's market cap stands at $2.7 billion. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) stock rose 11.71% to $1.24. The company's market cap stands at $356.5 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares increased by 11.68% to $0.37. The company's market cap stands at $9.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) shares fell 54.7% to $2.29 during Thursday's pre-market session. The company's market cap stands at $3.0 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock decreased by 27.26% to $0.88. The market value of their outstanding shares is at $43.9 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>FibroBiologics, Inc. - Common Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) shares declined by 20.01% to $12.2. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 19.54% to $2.87. The market value of their outstanding shares is at $12.3 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) stock decreased by 15.86% to $3.32. The company's market cap stands at $479.9 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares fell 15.52% to $0.38. The market value of their outstanding shares is at $9.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMWL

APLT

FBLG

FRES

HCTI

KALV

MHUA

RNLX

SCPX

VVOS

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Adaptive Biotechnologies shares are trading lower after the company reported mixed Q4 financial results.

Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript

TD Cowen analyst Daniel Brennan maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) today. The company's shares closed yes...

Adaptive Biotechnologies (ADPT) Receives a Buy from TD Cowen

Adaptive Biotechnologies Corporation 2024 Q2 - Results - Earnings Call Presentation

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adaptive Biotechnologies (ADPT – Research Report), V...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Adaptive Biotechnologies (ADPT – Research Report) today and set a price target of $...

Adaptive Biotechnologies (ADPT) Receives a Hold from Morgan Stanley

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVRx (CVRX – Research Report), Adaptive Biotechnolog...

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)

In a report released today, Sung Ji Nam from Scotiabank maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report), with a price ...

Scotiabank Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

Adaptive Biotechnologies Faces Tough Road Despite MRD Segment Growth (Rating Downgrade)

It's hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.

A Biotech Breakout Will Be Led By Small Caps

AAPL

ACHC

ADBE

AMZN

AVGO

BBIO

BMRN

CPRX

CVRX

DASH

DDOG

DLTR

DNLI

EWTX

FDMT

FERG

INBX

LBPH

MRNA

MSFT

NAMS

NTRA

ORIC

PACB

PEPG

PHVS

QDEL

ROIV

RPRX

RZLT

TMUS

TRVI

TTWO

VKTX

VRTX

WDAY

Press Releases

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

AbCellera Biologics

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. Class B Common Stock

BioLife Solns

ChromaDex

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Comments

Adaptive Biotechnologies

뉴스

에 대한 최신 뉴스 Adaptive Biotechnologies (NASDAQ:ADPT) 주식

화요일, 7월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌